PL2769727T3 - Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów - Google Patents
Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworówInfo
- Publication number
- PL2769727T3 PL2769727T3 PL12842329T PL12842329T PL2769727T3 PL 2769727 T3 PL2769727 T3 PL 2769727T3 PL 12842329 T PL12842329 T PL 12842329T PL 12842329 T PL12842329 T PL 12842329T PL 2769727 T3 PL2769727 T3 PL 2769727T3
- Authority
- PL
- Poland
- Prior art keywords
- deoxynucleoside
- tumors
- treatment
- nucleoside
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103143094A CN102499937A (zh) | 2011-03-02 | 2011-10-17 | 脱氧核苷与核苷组合在制备治疗肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2769727T3 true PL2769727T3 (pl) | 2017-01-31 |
Family
ID=48141653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12842329T PL2769727T3 (pl) | 2011-10-17 | 2012-10-16 | Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140309188A1 (pl) |
| EP (1) | EP2769727B1 (pl) |
| CN (2) | CN102172359A (pl) |
| DK (1) | DK2769727T3 (pl) |
| ES (1) | ES2587850T3 (pl) |
| HU (1) | HUE029492T2 (pl) |
| PL (1) | PL2769727T3 (pl) |
| WO (1) | WO2013056510A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102172359A (zh) * | 2011-03-02 | 2011-09-07 | 张始状 | 腺苷与核苷组合在制备治疗肿瘤药物中的应用 |
| CN104622887A (zh) * | 2014-11-24 | 2015-05-20 | 张始状 | 脱氧嘌呤核苷与其它核苷或碱基组合制备的抗肿瘤药物及其制备方法和应用 |
| CN115068495B (zh) * | 2022-07-05 | 2023-08-18 | 四川大学华西医院 | 核苷单体在制备抗肿瘤的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1941942A1 (de) * | 1969-08-18 | 1971-03-04 | Sylven Bengt Prof Dr | Neues pharmazeutisches Mittel |
| US5231086A (en) * | 1985-09-24 | 1993-07-27 | Item Development Aktiebolag | Continuous administration adenosine to increase myocardial blood flow |
| US5104859A (en) * | 1985-09-24 | 1992-04-14 | Solimedco Aktiebolag | Continuous administration of adenosine to reduce pulmonary vascular resistance |
| IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
| US6642211B2 (en) * | 2001-04-06 | 2003-11-04 | Wisconsin Alumni Research Foundation | Treatment of cancer with thymidine in combination with temozolamide |
| MXPA05012421A (es) * | 2003-05-16 | 2006-02-22 | Hybridon Inc | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. |
| EP1706079B1 (en) * | 2003-08-14 | 2013-02-20 | ThromboGenics N.V. | Antibodies against factor viii with modified glycosylation in the variable region |
| CN102172359A (zh) * | 2011-03-02 | 2011-09-07 | 张始状 | 腺苷与核苷组合在制备治疗肿瘤药物中的应用 |
-
2011
- 2011-03-02 CN CN2011100490469A patent/CN102172359A/zh active Pending
- 2011-10-17 CN CN2011103143094A patent/CN102499937A/zh active Pending
-
2012
- 2012-10-16 PL PL12842329T patent/PL2769727T3/pl unknown
- 2012-10-16 ES ES12842329.0T patent/ES2587850T3/es active Active
- 2012-10-16 DK DK12842329.0T patent/DK2769727T3/en active
- 2012-10-16 EP EP12842329.0A patent/EP2769727B1/en not_active Not-in-force
- 2012-10-16 WO PCT/CN2012/001392 patent/WO2013056510A1/zh active Application Filing
- 2012-10-16 HU HUE12842329A patent/HUE029492T2/en unknown
-
2014
- 2014-04-17 US US14/254,911 patent/US20140309188A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2769727A1 (en) | 2014-08-27 |
| ES2587850T3 (es) | 2016-10-27 |
| CN102499937A (zh) | 2012-06-20 |
| HUE029492T2 (en) | 2017-02-28 |
| DK2769727T3 (en) | 2016-08-29 |
| EP2769727A4 (en) | 2014-09-17 |
| CN102172359A (zh) | 2011-09-07 |
| EP2769727B1 (en) | 2016-05-18 |
| WO2013056510A1 (zh) | 2013-04-25 |
| US20140309188A1 (en) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
| HK1192758A1 (zh) | '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物 | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| HK1198133A1 (en) | Crizotinib for use in the treatment of cancer | |
| HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| HK1208625A1 (en) | Treatment methods using adenovirus | |
| SI2780332T1 (sl) | Morfolinilbenzotriazini za uporabo pri terapiji raka | |
| EP3733184C0 (en) | PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| HK1212255A1 (en) | Artemisinin and its derivatives for use in the treatment of kidney disease | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| HRP20180011T1 (hr) | Spojevi za uporabu u liječenju filariaza | |
| PL2872176T3 (pl) | Karboranyloporfiryny do stosowania w leczeniu raka | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| SG11201502317VA (en) | Telomerase inhibitors for use in therapy | |
| EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
| PL2769727T3 (pl) | Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| EP3104863C0 (en) | SALICYLATE FOR USE IN THE TREATMENT OF CANCER | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| GB201208770D0 (en) | Compounds for use in the treatment of adenovirus infections |